Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
1.080
+0.060 (5.88%)
Nov 22, 2024, 4:00 PM EST - Market closed
Clearside Biomedical Employees
Clearside Biomedical had 30 employees as of December 31, 2023. The number of employees decreased by 6 or -16.67% compared to the previous year.
Employees
30
Change (1Y)
-6
Growth (1Y)
-16.67%
Revenue / Employee
$256,767
Profits / Employee
-$1,062,600
Market Cap
81.91M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
P3 Health Partners | 400 |
I-Mab | 220 |
CASI Pharmaceuticals | 176 |
Adicet Bio | 143 |
Armata Pharmaceuticals | 66 |
Aerovate Therapeutics | 51 |
ESSA Pharma | 50 |
Oncolytics Biotech | 29 |
CLSD News
- 11 days ago - Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 16 days ago - Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema - GlobeNewsWire
- 17 days ago - Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference - GlobeNewsWire
- 19 days ago - Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - GlobeNewsWire
- 23 days ago - Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 - GlobeNewsWire
- 4 weeks ago - Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting - GlobeNewsWire
- 6 weeks ago - Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes - GlobeNewsWire
- 3 months ago - Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD - GlobeNewsWire